SPOTLIGHT: Galapagos inks deal with GSK
Belgium's Galapagos has agreed to collaborate with GlaxoSmithKline on new therapies for osteoarthritis. In the deal, Galapagos gains €4 million as a technology access fee and stands to gain up to €130 million in milestone payments for the successful launch of two products. "The alliance announced today fits very well into our strategy to provide turn-key drug discovery services to the biopharmaceutical industry," said Onno van de Stolpe, CEO of Galapagos. Report
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
